REGEND-001
- Generic Name
- REGEND-001
A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF)
Phase 2
Completed
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Biological: Placebo
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Regend Therapeutics
- Target Recruit Count
- 23
- Registration Number
- NCT06081621
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Ruijin Hospital, Shanghai Jiaotong University School Of Medicine, Shanghai, Shanghai, China
🇨🇳Renji Hospital, Shanghai Jiaotong University School Of Medicine, Shanghai, Shanghai, China
Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND001
- First Posted Date
- 2022-12-20
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Regend Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT05657184
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
🇨🇳Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath